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Novel class of Bi(III) hydroxamato complexes: synthesis, urease 
inhibitory activity and activity against H. pylori 
D. M. Keogan,
a
 B. Twamley,
b
 D. Fitzgerald-Hughes
c
 and D. M. Griffith
a
  
Reaction of Bi(NO3)3 with benzohydroxamic acid (Bha) and salicylhydroxamic acid (Sha) gives the novel Bi(III) complexes 
[Bi2(Bha-1H)2(-Bha-1H)2(
2-NO3)2] (1)  and [Bi6(CH3OH)2(
1-NO3)2(
2-NO3)(OH2)2(Sha-1H)12](NO3)2  (2). X-ray crystal structure of 
1 reveals two hydroxamato coordination modes; bidentate bridging (O, O’) and bidentate non-bridging (O, O’) and of 2 
reveals one coordination mode; bidentate bridging (O, O’).  1, specifically designed to and demonstrated to inhibit the 
activity of urease, exhibits excellent antibacterial activity against three strains of Helicobacter pylori with MIC ≥ 16 g/mL. 
Introduction,  
Helicobacter pylori (H. pylori) is a microaerophilic and 
neutralophilic Gram-negative bacterial pathogen that can 
colonise the human stomach. H. pylori infection can cause 
dyspepsia, peptic ulcer disease and gastric cancer, the second 
most common cause of cancer death in the world.
1
 The WHO 
classified H. pylori as a Class I Carcinogen in 1994 and 
significantly eradication of H. pylori infection reduces the 
incidence of gastric cancer.
2
 More recently, H. pylori has been 
linked with extragastric diseases such as cardiovascular 
disease, diabetes mellitus, sideropenic anemia and gallbladder 
cancer for example.
3
 
H. pylori has developed a number of ways to survive and 
colonise the harsh acidic environment of the gastric mucosa 
and in turn induce chronic infection. One of these mechanisms 
is “acid acclimation” whereby in the acidic environment of the 
stomach, periplasmic pH is adjusted by regulation of urease, 
UreI, and α-carbonic anhydrase.
4
 Urease, a dinuclear nickel(II) 
enzyme, catalyses the conversion of urea into ammonia and 
carbon dioxide.
4
 Upon a decrease in pH, UreI, a pH-gated urea 
channel in the cytoplasmic membrane, opens allowing urea to 
move into the cytoplasm. A concurrent increase in bacterial 
urease activity, produces the ammonia required to neutralise 
protons entering the cytoplasm and maintain the pH 
microenvironment at c. 6.8.
4
 Urease, which accounts for  10–
15% of total protein by weight,
5
 can be considered to be H. 
pylori’s achilles heel as its activity is vital to H. pylori’s ability to 
survive and colonise the harsh acidic environment of the 
gastric mucosa and in turn induce chronic infection.
4
 
A standard triple drug treatment (triple therapy) of two 
antibiotics in addition to a proton pump inhibitor (PPI) is the 
first-line treatment for H. pylori.
6
 Significantly though, H. pylori 
infections are becoming increasingly difficult to eradicate due 
to antibiotic resistance. Antibacterial drug resistance is a 
serious global health problem and the prospect of untreatable 
bacterial infections is becoming a reality. H. pylori resistance 
rates for example in Europe and Asia for clarithromycin are 
17.5 and 21.5% and for metronidazole are 34.9% and 95.4% 
respectively.
7, 8
  
Consequently bismuth (Bi)-containing quadruple therapies are 
increasingly recommended as the first-line treatment in a 
number of countries.
6, 9, 10
 Bismuth subsalicylate (BSS), colloidal 
bismuth subcitrate (CBS) and the more recently developed 
ranitidine bismuth citrate (RBS), are administered however 
without an exact understanding of their structure,
11, 12
 
behaviour in biological environment or indeed their 
mechanisms of action.
13
 Recently innovative metallomic and 
metalloproteomic approaches have aided identification of Bi 
targeting proteins in H. pylori such as HspA, Ef-Tu, NapA and 
urease (UreA and UreB) and revealed that Bi(III) has a high 
selectivity for cysteines and histidines, particularly motif 
patterns of CXnC, CXnH and HXnH. Evidence therefore suggests 
that Bi interference with metal homeostasis and oxidation 
reduction processes may be important.
14-18
  
Significantly it was recently demonstrated that glutathione and  
multidrug resistance protein transporter remove Bi from 
human cells, thereby protecting the human body from 
associated toxicity and also providing a level of selectivity 
between human cells and bacterial cells that lack glutathione 
such as H. pylori.
19
 
Thus there is renewed interest in the development of novel Bi-
based drugs and investigation of their mode of action.
13, 20-25
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Hydroxamic acids, a family of important bioligands, of general 
formula RCONR’OH, are well-known metal chelators, 
metalloenzyme inhibitors and NO donors, Figure 1.
26, 27
  
 
 
 
 
 
 
 
 
 
 
Figure 1 Representative structures of hydroxamic acids. 
Significantly acetohydroxamic acid and alternative hydroxamic 
acids are potent inhibitors of urease. Acetohydroxamic acid for 
example has been demonstrated to bridge the dinuclear Ni(II) 
active site of the urease enzyme.
5
  
We therefore sought to combine the established antibacterial 
properties of Bi with the urease inhibitory properties of hydroxamic 
acids and develop structurally well-defined Bi hydroxamic acid 
complexes as potential anti-H. pylori agents. We hypothesise that 
such complexes will hydrolyse in the low pH of gastric juice 
releasing insoluble Bi salts such as BiOCl and free hydroxamic acids, 
i.e. co-deliver Bi and hydroxamic acids and activate at the site of 
action. In the gastric environment Bi salts and/or Bi gastrointestinal 
biomolecular complexes will exhibit conventional antibacterial 
activity against H. pylori. In addition free hydroxamic acids will 
inhibit the activity of H. pylori urease drastically reducing its ability 
to buffer the pH of its microenvironment. 
Results and discussion 
Synthesis 
Reaction of hydroxamic acids (L) with Bi(NO3)3 in ethanol gave 
novel complexes of type Bi(L-1H)2NO3, representing a novel 
class of Bi hydroxamato complexes. Andrews et al. recently 
reported Bi hydroximato/ hydroxamato complexes on reaction 
of hydroxamic acids with Bi(O
t
Bu)3 or BiPh3.
24, 25
 
Reaction of benzohydroxamic acid (Bha) with Bi(NO3)3 in 
absolute ethanol under reflux for 5 hours afforded the novel 
dinuclear Bi(III) complex  [Bi2(Bha-1H)2(-Bha-1H)2(
2
-NO3)2] (1), 
Scheme 1.  Crystals suitable for single crystal X-ray diffraction 
were obtained of 1 from recrystallization in methanol.  
 
 
 
Scheme 1 Synthesis of Bi hydroxamato complex [Bi2(Bha-1H)2(-Bha-1H)2(
2-NO3)2] (1). 
In the 
1
H NMR spectra (d4-MeOD) of 1 for example complex no 
signals associated with the hydroxamic acid protons (N-H and 
O-H) are observed as expected. In 1 the most significant shift is 
that of an aromatic doublet, associated with protons closest to 
the hydroxamic acid group at the 2 and 6 positions on the 
aromatic ring, from 7.73 in the free ligand to 7.84.  
The IR spectra of 1 exhibits distinctive (C=O) at 1595 cm
−1 
and 
the characteristic
 
shift associated with (O,O’) hydroxamato 
coordination when compared to the corresponding (C=O) of 
the uncoordinated ligands (Bha, 1647 cm
−1
).
28
   
ESI-MS in the positive mode was used to identify product ion 
fragments associated with BiNO3 (271.8) Bi(Bha-1H) (345.7), 
Bi(NO3)(Bha-1H) (407.7), Bi(Bha-1H)2 (480.7) for 1. 
Reaction of salicylhydroxamic acid (Sha) with Bi(NO3)3 in 
absolute ethanol under reflux for 5 hours afforded a Bi(III) 
complex  of general formula [Bi(NO3)(Sha-1H)2]n, which upon 
recrystallisation from methanol gave [Bi6(CH3OH)2(
1
-NO3)2(
2
-
NO3)2(OH2)2(Sha-1H)12].(CH3OH)4.(H2O)4  2.  
 
X-ray Crystallography 
The solid state structure of 1 and 2 are shown in Figure 2. Both 
complexes crystallize in the Pī space group and are completed 
by inversion symmetry.  
The formula of 1 consists of the charge neutral complex 
[Bi2(Bha-1H)2(-Bha-1H)2(
2
-NO3)2] with a solvent MeOH 
molecule. The hydroxamato ligands and MeOH molecule 
display disorder with each phenyl ring occupying two positions 
and the solvent spread over six positions. In the main core of 
the complex each Bi centre is chelated by two ligands via Bi-O 
bonds (Bi1-O1 2.201(5); Bi1-O4 2.409(5)Å and Bi1-O11 
2.234(4); Bi1-O14 2.276(5)Å) and a nitrato group (Bi1-O19 
2.519(5); Bi1-O22 2.755(5)Å). The bismuth atoms are linked by 
two µ-oxo bridges via the benzohydroxamato groups forming a 
planar Bi2-µ-O2 dimer oxygen (Bi1-O11 2.234(4); Bi1-O11a
$1
 
2.674(5)Å; Bi-O-Bi
$1
 113.23(19)°; $1 = symmetry 
transformation =  -x+1,-y+1,-z+1). Significantly 1 exhibits two 
distinct and Bi hydroxamato binding modes: bidentate bridging 
(O, O’) and bidentate non-bridging (O, O’), Scheme 1 and 
Figure 2. 
Andrews and coworkers recently published the first X-ray crystal 
structure of a Bi hydroxamato complex; a unique Bi34 oxido-cluster, 
[Bi34O22(Bha-2H)22(Bha-1H)14(DMSO)6], isolated on dissolution of a 
[Bi2(Bha-2H)3] complex in dmso/toluene. This complex features both 
doubly deprotonated benzohydroximato and singly deprotonated 
hydroxamato ligands.
24, 25
 
The formula of 2 consists of the cationic complex 
[Bi6(CH3OH)2(
1
-NO3)2(
2
-NO3)2(OH2)2(Sha-1H)12]
2+ 
with two 
isolated NO3
-
 counterions to balance the charge as well as 
solvent molecules (4 water and 4 methanol). The complex 
itself consists of 6 bismuth centres, each chelated by two 
salicylhydroxamato ligands. One terminal bismuth atom, Bi2, is 
bonded to a H2O and methanol; the other terminal bismuth, 
Bi3, to a NO3
-
 group. Each central Bi atom is also bonded to 
one NO3
-
 group. The bismuth atoms are bridged by the 
salicylhydroxamato ligands to form terminal Bi2-µ-O3 (Bi-O 
range = 2.226-2.82Å, Bi-O-Bi range = 96.3(1)-101.4(1)°) and 
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planar central Bi2-µ-O2 dimers (Bi1-O21 2.337(2), O21-Bi1
$1
 
2.577(2)Å; Bi-O-Bi 117.1(1)°). The dimers are linked together 
by additional µ-O bonding via the amido hydroxy oxygen (O10-
Bi1 2.256(2), O10-Bi3
$3
, 2.721(2)Å; Bi-O-Bi 121.6(1)°: O32-Bi1 
2.521(2), O32-Bi2 2.230(2)Å; Bi-O-Bi 115.8(1)°: $3 = symmetry 
transformation =  -x+1,-y+1,-z+1). In contrast to 1, 2 exhibits 
only the bidentate bridging (O, O’) hydroxamato coordination 
mode, Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Molecular structure of [Bi2(Bha-1H)2(-Bha-1H)2(
2-NO3)2].CH3OH (1, top, 
displacement ellipsoids shown at 50%, disordered phenyl carbon atoms and all 
hydrogen atoms omitted for clarity)  and [Bi6(CH3OH)2(1-NO3)2(2-NO3)(OH2)2(Sha-
1H)12](NO3)2. (CH3OH)4.(H2O)4 (2,bottom,  displacement ellipsoids shown at 50%, partial 
labelling and hydrogen atoms omitted for clarity). 
Andrews et. al. recently reported the X-ray crystal structure of 
a Bi salicylhydroximato/hydroxamato dmso complex {[Bi(Sha-
2H)(Sha-1H)(DMSO)2][Bi(Sha-2H)(Sha-1H)(DMSO)]·DMSO}∞.
25
 
The coordination environment around each bismuth atom in 1 
and 2 can be completed by including slightly longer O-Bi 
distances (Bi-O range complex 1 =2.2-3.03 Å; complex 2 = 2.2 – 
3.2Å), Figure 3.  
In complex 1, this involves an intermolecular Bi-O interaction 
(Bi_O1
$2
, 3.034(5)Å; $2 = 1+x, y, z) and results in two 8 
coordinate Bi atoms with edge shared distorted dodecahedral 
geometry. In complex 2, Bi1 and Bi3 have a coordination 
number 9 with distorted monocapped square antiprismatic 
geometry, whereas Bi2 has a coordination of 8 with distorted 
dodecahedral geometry, Figure 3. 
 
 
 
 
 
 
 
 
 
 
                                                              
 
 
 
 
 
 
 
 
 
 
Figure 3. Polyhedral coordination environment around Bi in 1 (top) and 2 
(bottom). Phenyl rings removed from ligands for clarity. 
Biological Testing 
Complex 1, the first reported example of a Bi complex 
specifically designed to inhibit the activity of urease was 
selected to be tested for its urease inhibitory activity and activity 
against H. pylori given it is free of undesirable coordinated solvent 
molecules and therefore a suitable candidate as an anti H. pylori 
agent.  Complex 2, which contains coordinated MeOH molecules, is 
not a suitable drug candidate.  
Urease Inhibitory Activity 
Urease 1 and its corresponding hydroxamic acid ligand Bha  
 
Figure 4 % Inhibition of the activity of Jack Bean Urease for compound 1, Bha and BSS 
over the range 0.1-10 mM (n=3). 
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inhibited the activity of Jack Bean urease in vitro (e.g. 96 % 
inhibition and 83 % inhibition at 10 mM respectively), Figure 4. In 
contrast the clinically used Bi drug, BSS, showed poor inhibitory 
activity (19 %) even at 10 mM, Figure 4. The urease inhibitory 
activity of 1 is primarily attributed to the urease inhibitory 
properties of its benzohydroxamic ligand.  
It is noteworthy that Sun et al. demonstrated both competitive 
and non-competitive inhibition of urease by Bi(III) using a 
number of complexes including RBC. Using NMR spectroscopic 
and site-directed mutagenesis studies they indicate that Bi(III) 
can bind to the highly conserved cysteine residue (Cys319) 
located at the entrance of the urease active site.
29
 Therefore Bi 
can potentially also contribute to urease inhibition. 
Antibacterial Activity 
The minimum inhibitory concentrations (MICs) of compound 1 
and its hydroxamic acid ligand Bha and BSS were determined 
against three laboratory strains of H. pylori: 26695, J99 and 
60190 using the agar diffusion method (recommended by the 
Clinical and Laboratory Standards Institute, CLSI),
30
 at 
compound concentrations ranging from 0.5 to 64 g/mL. MICs 
of 16, g/mL were determined for compound 1 against 26696, 
J99 and 60190, which were comparable to the MICs for BSS 
(16, g/mL) and less than the MIC for the free ligand Bha, (32  
g/mL), which also exhibited considerable activity. 
Table 1 MIC’s for Complexes 1 against H. pylori (n=3). 
 
Andrews and coworkers recently reported alternative Bi(III) 
benzohydroxamato/hydroximato complexes; [Bi2(Bha-2H)3]∞, 
[Bi(Bha-1H)3] and [Bi(Bha-2H)(Bha-1H)] with superior activity 
against H. pylori strains 26695 and 60190 with MIC’s ranging 
from 0.09 to 1.56 g/mL and likely due to superior H. pylori 
uptake.
24, 25
  
Conclusions 
Herein we report a novel class of Bi hydroxamato complexes of 
type Bi(L-1H)2.NO3 specifically designed to and demonstrated to 
inhibit urease, H. pylori’s Achilles heel. Reaction of Bi(NO3)3 with 
benzohydroxamic acid (Bha) and salicylhydroxamic acid (Sha) gives 
the novel Bi(III) complexes [Bi2(Bha-1H)2(-Bha-1H)2(
2
-NO3)2] and 
[Bi6(CH3OH)2(
1
-NO3)2(
2
-NO3)(OH2)2(Sha-1H)12](NO3)2. X-ray 
crystal structure of 1 reveals two hydroxamato coordination 
modes; bidentate bridging (O, O’) and bidentate non-bridging 
(O, O’) and of 2 reveals one coordination mode; bidentate 
bridging (O, O’).  1 exhibits excellent antibacterial activity 
against three strains of H. pylori with MIC ≥ 16 g/mL. 
Further development of bismuth complexes as effective 
urease inhibitors will be undertaken and their potential activity 
against H. pylori at low pH and increased urease dependent 
conditions investigated.  
Experimental 
Materials and instrumentation 
Benzohydroxamic acid was purchased from Tokyo Chemical 
Industry Ltd. Salicylhydroxamic acid, Bismuth Subsalicylate, 
Bi(NO3)3.5H2O and deuterated solvents were purchased from 
Sigma Aldrich and used without further purification. IR spectra 
were recorded using a Bruker VERTEX 70/70v FT-IR 
spectrometer using KBr discs (4000-400 cm
-1
). The spectra 
were analysed using OPUS software. 
1
H NMR and 
13
C NMR 
spectra were recorded on a Bruker Avance 400 NMR 
spectrometer. The spectra were analysed using MestReNova 
software. The residual undeuterated d4-Methanol signal at 
3.31 ppm was used as an internal reference. Mass 
spectrometry experiments were performed on an Advion 
Expression Compact Mass Spectrometer where 10 μL of the 
samples were injected in 300 μL of methanol:water:formic acid 
(90:9:1 v/v). The mass spectrometry data were acquired both 
in positive and negative ion modes and the spectra analysed 
using the Advion Mass Express software programme. 
Elemental analysis (C, H and N) was performed at the 
Microanalytical Laboratory, School of Chemistry and Chemical 
Biology, University College Dublin, Ireland. 
Isolated Jack bean (Canavalia ensiformis) urease and Fetal 
Bovine Serum were purchased from Sigma Aldrich. H. pylori 
strains were purchased from The American Type Culture 
Collection (ATCC). Tryptic Soy Agar (TSA) + 5% sheep blood (SB) 
plates were purchased from Fannin Ireland. Defibrinated 
Horse blood was purchased from Thermo Scientific. GenBags, 
GenBoxes and microaerophilic environment producing sachets 
(Biomerieux) were purchased from Cruinn Ltd. 
 
Urease 
Assays were prepared in 96-well microtiter plates. Urease 
enzyme (5-15 I.U.) was pre-incubated at 25 
o
C for 30 min with 
inhibitors at 0.1, 1 and 10mM in 100mM potassium phosphate 
buffer, pH 6.8 in 50 mL volumes. Following pre-incubation, 
enzyme assay mixtures were added containing 100 mM 
potassium phosphate buffer, pH 6.8, 150 mM urea, 0.002% 
phenol red in a final volume of 200 mL.
31
 Linear changes in 
absorbance at 565 nm at 37 
o
C, associated with the change in 
absorption of phenol red due to production of ammonia, were 
measured over a 15 min period. Rates of inhibition were 
determined and plotted as percentage inhibition versus 
control. 
 
Bacterial strains and culture conditions 
Commercial H. pylori strains J99, 60190 and 26695 were 
routinely cultured on TSA supplemented with 5% SB. The 
plates were incubated at 37 
o
C for 4-7 days under 
microaerophilic conditions using GenBag Microaer
TM
 according 
to the supplier’s instructions. 
Determination of Minimum Inhibitory Concentration (MIC) 
The MIC of the bismuth complexes was determined by the 
Agar Dilution Method, which is recommended by the Clinical 
H. pylori strain 1 (g/ml) Bha (g/ml) BSS (g/ml) 
26695 16 32 16 
J99 16 32 16 
60190 16 32 16 
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and Laboratory Standards Institute (CLSI) for susceptibility 
testing of H. Pylori.
30
  
H. pylori cultures were cultured on TSA + 5% SB. Single 
colonies were re-suspended in 0.9 % NaCl to a density of a 4 
McFarland standard (approximately 10
8
 CFU mL
-1
), measured 
using a Densicheck instrument (Bioemerieux Ltd). Aliquots (5 
μl) of these suspensions were then dropped onto the TSA 
plates containing doubling dilutions of test compounds, 
ranging in concentration from 64 μg mL
-1
 to 0.5 μg mL
-1
. Each 
compound was tested alongside BSS in comparable 
concentrations and a control plate with no compound as a 
positive control. The MIC’s, defined as the lowest 
concentration at which no growth was observed, were 
determined by examination of the plates after incubation 
under microaerophilic conditions for 3-5 days at 37 
o
C. 
 
Synthesis 
Synthesis of [Bi2(Bha-1H)2(-Bha-1H)2(
2
-NO3)2] (1) 
Bi(NO3)3.5H2O (485 mg, 1 mmol) and benzohydroxamic acid 
(302 mg, 2.1 mmol) were placed in a clean dry round 
bottomed flask. Ethanol (50ml) was added and the mixture 
was stirred for 30 mins and subsequently heated to reflux for 5 
hours. The clear solution was allowed to cool and the solution 
was filtered regardless. The clear filtrate was then condensed 
in vacuo to c. 10 ml. On the addition of H2O (5 ml) a white solid 
precipitated, which was filtered, and dried to give compound 
1, 410mg (77%), max (cm
‐1
): 1595 (s, C=O), 1560 (s, C-N), 1477,  
1385 (s, N-O). Elemental analysis; (C28H24Bi2N6O14) Calc. 
(Found): C 30.95 (30.84), H 2.23 (1.91), N 7.74 (7.45) %. 
1
H 
NMR (400 MHz, CD3OD, 25 °C): δH 7.85 (dd, J = 7.1, 1.5 Hz, 2H, 
Aromatic H), 7.56 (d, J = 7.4 Hz, 1H, aromatic H), 7.52 – 7.46 
(m, 2H, Aromatic H); 
13
C NMR (100.1 MHz, CD3OD, 25 °C): δC 
165.6, 133.0, 131.5, 130.1, 128.0. MS (ESI+) m/z: 271.8 
(Bi(NO3)), 345.7 (Bi(Bha-1H)), 407.7 (Bi(NO3)(Bha-1H)), 
480.7(Bi(Bha-1H)2). Single crystals of [Bi2(Bha-1H)2(-Bha-1H)2(
2
-
NO3)2].CH3OH were isolated upon recrystallization of 
compound 1 from methanol. 
Synthesis of [Bi6(CH3OH)2(
1
-NO3)2(
2
-NO3)2(OH2)2(Sha-1H)12] (2) 
Bi(NO3)3.5H2O (905 mg, 1.86 mmol) and salicylhydroxamic acid 
(856 mg, 5.59 mmol) were placed in a clean dry round 
bottomed flask. Ethanol (80 ml) was added and the mixture 
was stirred for 30 mins and subsequently heated to reflux for 5 
hours. The clear solution was allowed to cool and filtered 
regardless. The clear filtrate was then condensed in vacuo to c. 
10 ml. On the addition of H2O (5 ml) a white solid precipitated, 
which was filtered, and dried, 750mg. max (cm
‐1
): 1604 (s, 
C=O), 1560 (s, C-N), 1480, 1383 (s, N-O). Elemental analysis; 
31.06, H 2.08, N 6.75 %. 
1
H NMR (400 MHz, CD3OD, 25 °C): δH 
7.85 (d, J = 6.2 Hz, 1H, aromatic H), 7.31 (t, J = 6.9 Hz, 1H, 
aromatic H), 6.87 (m, 2H, aromatic H). 
13
C NMR (100.1 MHz, 
CD3OD, 25°C): δC 166.1, 157.6, 134.3, 130.4, 120.8, 117.2, 
116.8. MS (ESI+) m/z: [Bi(NO3)(Sha-1H)]
+
 423.9, [Bi(Sha-1H)2]
+
 
513.8.  
Single crystals of [Bi6(CH3OH)2(
1
-NO3)2(
2
-NO3)2(OH2)2(Sha-
1H)12].(CH3OH)4(H2O)4(NO3)2 2 were isolated on recrystallization 
of white solid from methanol.  
 
Crystallographic data 
Complex 1 
A specimen of C29H28Bi2N6O15, approximate dimensions 0.030 
mm x 0.050 mm x 0.210 mm, was used for the X-ray 
crystallographic analysis. The X-ray intensity data were 
measured at 100(2)K using an Oxford Cryosystems Cobra low 
temperature device using a MiTeGen micromount. See Table 1 
for collection parameters and exposure time. Bruker APEX 
software was used to correct for Lorentz and polarization 
effects.
32
  
A total of 1027 frames were collected. The total exposure time 
was 2.85 hours. The frames were integrated with the Bruker 
SAINT software package using a wide-frame algorithm. The 
integration of the data using a triclinic unit cell yielded a total 
of 32284 reflections to a maximum θ angle of 27.53° (0.77 Å 
resolution), of which 4213 were independent (average 
redundancy 7.663, completeness = 100.0%, Rint = 6.26%, Rsig = 
4.44%) and 3768 (89.44%) were greater than 2σ(F
2
). The final 
cell constants of a = 4.8467(4) Å, b = 13.1798(12) Å, c = 
15.0042(14) Å, α = 74.217(3)°, β = 85.628(3)°, γ = 82.567(3)°, 
volume = 913.71(14) Å
3
, are based upon the refinement of the 
XYZ-centroids of 2486 reflections above 20 σ(I) with 4.823° < 
2θ < 43.96°. Data were corrected for absorption effects using 
the multi-scan method (SADABS).
33
  The ratio of minimum to 
maximum apparent transmission was 0.620. The calculated 
minimum and maximum transmission coefficients (based on 
crystal size) are 0.4625 and 0.7456.  
The structure was solved and refined using the Bruker SHELXTL 
Software Package,
34
 using the space group Pī, with Z = 1 for the 
formula unit, C29H28Bi2N6O15. The final anisotropic full-matrix 
least-squares refinement on F
2
 with 251 variables converged at 
R1 = 3.71%, for the observed data and wR2 = 9.35% for all 
data. The goodness-of-fit was 1.084. The largest peak in the 
final difference electron density synthesis was 2.302 e
-
/Å
3
 and 
the largest hole was -1.477 e
-
/Å
3
 with an RMS deviation of 
0.227 e
-
/Å
3
. On the basis of the final model, the calculated 
density was 2.033 g/cm
3
 and F(000), 530 e
-
. 
Refinement Note: The phenyl ring systems were disordered 
50:50% and were modelled with restraints and constraints 
(ISOR and EADP). The disordered MeOH solvent molecule was 
modelled as 50% occupied in three locations in the asymmetric 
unit. Restraints and constraints were applied to model the 
disorder (DFIX, EADP and ISOR). Each disordered MeOH moiety 
refined as 17:18:15% occupied. 
Refinement Note: N-H and O-H hydrogen atoms were located 
and refined using a DFIX restraint: 
O5, O6, O16, O17, O18 and N9, N20, N31, N42, N53, N64. 
Complex 2 
A specimen of C90H108Bi6N18O66, approximate dimensions 0.050 
mm x 0.080 mm x 0.150 mm, was used for the X-ray 
ARTICLE Journal Name 
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crystallographic analysis. The X-ray intensity data were 
measured at 100(2)K using an Oxford Cryosystems Cobra low 
temperature device using a MiTeGen micromount. See Table 1 
for collection parameters and exposure time. Bruker APEX 
software was used to correct for Lorentz and polarization 
effects.
32
 
A total of 1731 frames were collected. The total exposure time 
was 4.81 hours. The integration of the data using a triclinic unit 
cell yielded a total of 111802 reflections to a maximum θ angle 
of 30.14° (0.71 Å resolution), of which 17529 were 
independent (average redundancy 6.378, completeness = 
99.4%, Rint = 4.43%, Rsig = 3.33%) and 14300 (81.58%) were 
greater than 2σ(F
2
). The final cell constants of a = 15.0432(6) Å, 
b = 15.2366(5) Å, c = 16.5434(6) Å, α = 112.5660(10)°, β = 
116.5850(10)°, γ = 94.4850(10)°, volume = 2984.48(19) Å
3
, are 
based upon the refinement of the XYZ-centroids of reflections 
above 20 σ(I). Data were corrected for absorption effects using 
the numerical method (SADABS).
33
 The calculated minimum 
and maximum transmission coefficients (based on crystal size) 
are 0.4747 and 0.7837.  
The structure was solved and refined using the Bruker SHELXTL 
Software Package,
34
 using the space group Pī, with Z = 1 for the 
formula unit, C90H108Bi6N18O66. The final anisotropic full-matrix 
least-squares refinement on F
2
 with 827 variables converged at 
R1 = 2.54%, for the observed data and wR2 = 5.33% for all 
data. The goodness-of-fit was 1.004. The largest peak in the 
final difference electron density synthesis was 1.894 e
-
/Å
3
 and 
the largest hole was -1.451 e
-
/Å
3
 with an RMS deviation of 
0.154 e
-
/Å
3
. On the basis of the final model, the calculated 
density was 2.087 g/cm
3
 and F(000), 1800 e
-
. 
Refinement Note: N-H and O-H hydrogen atoms were located 
and refined using a DFIX restraint: 
O5, O6, O16, O17, O18 and N9, N20, N31, N42, N53, N64. 
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